This study was performed to evaluate the anticancer effects of tolerable doses of metformin 19 with or without medroxyprogesterone (MPA) in endometrial cancer cells. Cell viability, cell 20 invasion, and levels of matrix metallopeptidase (MMP) and transforming growth factor (TGF)-21 β1 were analyzed using three human endometrial adenocarcinoma cell lines (Ishikawa, KLE, 22 and USPC) after treatment with different dose combinations of MPA (0, 10 µM) and metformin 23 (0, 100, 1000 µM). Combining metformin (0, 100, 1000 µM) and 10 µM MPA induced 24 significantly decreased cell viability in a time-and dose-dependent manner in Ishikawa cells, 25 but not in KLE and USPC cells. There was no dose-or time-dependent cell growth inhibition, 26 or positive western blot results for the expression of progesterone receptors and phospho-27 AMPKα, following treatment with any combination of metformin (0, 100, 1000 µM) and 10 28 µM MPA in KLE and USPC cells. In KLE cells, metformin treatment alone significantly 29 inhibited cell invasion in a dose-dependent manner (1.31±0.05, 0.94±0.04, 0.83±0.05 at 0, 100 30 µM, 1000 µM, respectively; p<0.0005). The inhibitory effect of metformin was reversed to 31 create a stimulating effect when metformin was combined with 10 µM MPA (1.10±0.05, 32 1.42±0.18, 1.41±0.26 at 0, 100, 1000 µM, respectively; p<0.005). MMP-9 and TGF-β1 showed 33 similar trends in terms of cell invasion in KLE cells. In conclusion, the anti-invasive effect of 34 metformin in KLE cells was completely reversed to the state of no treatment by the addition of 35 MPA; this might be mediated through MMP-9 and TGF-β1. Our study suggests the possibility 36 of these combinations doing harm, rather than good, under some conditions. 3 37
Introduction 38
Uterine corpus cancer was found to be the 4th most common cancer in women in 2018; 39 the estimated number of new cases was 63,230, accounting for 7% of all new cancer diagnoses 40 in women (1). Endometrial cancer constitutes the majority of uterine cancers, excluding 41 uncommon subtypes of stromal or mesenchymal sarcomas, which account for approximately 42 3% of all uterine cancers. Despite multimodal treatment approaches, type I poorly 43 differentiated endometrioid adenocarcinoma and type II cancers, including uterine serous 44 papillary cancer (USPC) without estrogen receptor (ER) and progesterone receptor (PR) 45 expression, have very poor prognosis unlike type I well-differentiated endometrioid 46 adenocarcinoma, which expresses ER and PR. Among the systemic hormonal therapies 47 considered for recurrent, metastatic, or high-risk disease, progestin is the most commonly used, 48 mainly in the form of medroxyprogesterone acetate (MPA). However, clinical guidelines 49 recommend that MPA may only be used for lower-grade endometrioid histology. This is based 50 on previous reports that the highest response rates were noted in low-grade, ER-positive tumors 51 of up to 55% (2, 3). In addition, long-term continuous use of progestin was known to cause a 52 loss of effect of PR activation (2). Therefore, development of a new treatment strategy for 53 groups of cancer with poorer prognosis is urgent. and USPC cells were cultured in RPMI1640 medium (Life Technologies, CA, USA) with 83 10% FBS, 2 mM/L glutamine, and 0.5% P/S. All the cells were cultured in an incubator at 84 37℃ under a humidified atmosphere containing 5% CO2. 85 86 Dose setup of metformin treatments 87 Tolerable doses of metformin (500 mg twice/day) could achieve a plasma 88 concentration of around 1 mg/L (14). Although the maximal approved total daily dose of 89 metformin for treatment of diabetes mellitus is 2.5 g (35 mg/kg body weight)(8), slow but 90 progressive increase of fasting lactic acid levels during metformin treatment with multiple 91 doses from 100 to 850 mg twice a day suggested that; the higher dose of metformin, the higher 92 risk of lactic acidosis (14). Therapeutic plasma concentrations or ranges of metformin 93 measured in previous studies of type 2 diabetes ranged from 0.129 to 90 mg/L (9). Therefore, 94 1 mM (129.2 mg/L) was set as a maximal concentration of metformin for our experiment, To increase cell growth rate, all cells were seeded in 12-well plates (Corning Life 100 Sciences, NY, USA) at 10,000 cells/cm 2 , and the cell number was counted at 24-hour intervals 101 until 96 hours. For cell counting, the medium was removed from the cell culture plates, washed 102 twice with phosphate buffer saline (PBS), and then treated with 0.25% trypsin for 5 min at 103 37 °C. The trypsin-treated cells were collected in a 15 ml tube, washed twice with the culture 104 medium, and counted three times using the Adam-MC automatic cell counter (NanoEntek, 6 105 Korea). Viable cells were more accurately measured using an advanced image analysis 106 program of Adam-MC cell counter.
107
Cell survival analysis was performed to investigate the effects of metformin (Sigma-108 Aldrich) and/or MPA (Sigma-Aldrich) on endometrial cancer cell lines. Cells were seeded into 109 a 96 well plate (Ishikawa 5*10 4 /㎠, KLE 2*10 4 /㎠ and USPC 3*10 4 /㎠). The next day, cells 110 were treated with 100 µM and 1 mM of metformin, with or without 10 µM of MPA. Then, 111 survival rates of cells were analyzed after 24 hours and 48 hours of drug treatment using a 3-
112
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay kit (DoGen Co., 
Cell invasion assay and ELISA

127
To perform invasion assays, we first coated matrigel (BD science, CA, USA) on a 7 128 transwell membrane with 8 μm pores (Corning Life Sciences, NY, USA) at 37℃ for 2hours, 129 and seeded 8*10 4 cells/cm 2 into the transwell membrane. The next morning, the cells were 130 starved for 2 hours in culture medium without FBS and the outside of the transwell was 131 replaced with a 5% charcoal strip FBS (Life Technologies) containing medium to induce 132 invasion for 24 hours in a 37℃, humidified atmosphere containing 5% CO2; anticancer drugs 133 were treated according to the conditions at the time of the exchange of the medium. The next 134 day, all the cells in the transwells were removed, and the transwells were inverted to stain the 135 transferred cells with 0.2% crystal violet. The stained cells were de-stained with 2% SDS and 136 absorbance was measured at 560 nm.
137
For quantitative analysis of cell migration related proteins, the secretion levels of 138 Matrix metallopeptidase (MMP)-2 and -9 (R&D system, MN, USA) and transforming growth 139 factor (TGF)-β1 (R&D system, MN, USA) were checked using ELISA kits. First, all cells were 140 plated at 9*10 4 cells/cm 2 into a 24 well plate (Corning Life Sciences, NY, USA) and starved 141 for 2 hours in culture medium without FBS. The anticancer drugs were treated according to the 142 conditions while the culture medium was exchanged with the complete medium. After 24 hours, 143 the cultures were collected without cells and analyzed. An ELISA was performed according to 144 the supplier protocol (https://www.rndsystems.com/). Inc., CA, USA). The differences between the two groups were determined using a two-tailed Cell growth and growth inhibition by tolerable doses of metformin 153 and MPA in endometrial cancer cell lines 154 We found that USPC cells had the fastest growth rate among the three endometrial 155 cancer cells during 96-hour incubation, followed by Ishikawa and KLE cells ( Fig 1A and 1B) .
156
The MTT assay showed that treatment with metformin alone at ≤ 1000 µM for 48 hours exerted 157 significant inhibitory effects on the cell viability of Ishikawa, KLE, and USPC cells in a dose-158 dependent, but not in a time-dependent manner ( Fig 1C-1E ). In Ishikawa cells, a combination 159 of metformin (0, 100, 1000 µM) and 10 µM MPA induced a significant decrease in cell viability 160 in a time-and dose-dependent manner ( Fig 1C) . Addition of 10 µM MPA to metformin 161 significantly inhibited cell viability compared to that by metformin alone at each dose (0, 100, 162 1000 µM), respectively, in Ishikawa, but not in KLE and USPC cells. There was no dose-or time-dependent cell growth inhibition or positive western blot results for PR and p-AMPKα expression when any combination of metformin (0, 100, 1000 196 µM) and 10 µM MPA were used in KLE and USPC cells. We further performed an invasion 197 assay ( Fig 3A) , which showed that metformin treatment alone did not induce any significant 198 changes in cell invasion in Ishikawa and USPC cells (Fig 3B and 3D) . In KLE cells (Fig 3C) , (0.84±0.08) ( Fig 3B) . There was no significant effect of metformin and MPA combination on 210 the invasion of USPC cells ( Fig 3D) . MMP-2 showed no significant changes in response to the treatments in all three cell 220 lines (Fig 4A-4C) . However, although decreased MMP-9 induced by metformin treatment 221 alone was not statistically significant, MMP-9 showed the same trends of rise with cell invasion 222 in KLE cells when treated in combination with metformin (0, 100, 1000 µM) and 10 µM MPA 223 (3.99±0.90 for control, 5.83±1.04, 7.68±1.38, 8.05±2.09 ng/ml, respectively; p<0.05) ( Fig 4E) . 224 Otherwise, there were no significant changes in MMP-9 expression in Ishikawa and USPC 225 cells ( Fig 4D and 4F) . TGF-β1 also showed similar trends to MMP-9, which was in concordance with the 233 change in cell invasion ( Fig 5B) . TGF-β1 secretion was significantly decreased when KLE 234 cells were treated with 1000 µM metformin alone compared to that in control cells (62.76±2.18 235 vs. 54.19±3.60 pg/mL; p=0.024). Furthermore, TGF-β1 also exhibited the reverse pattern when 236 treated with a combination of 1000 µM metformin and 10 µM MPA (62.76±2.18 vs. 237 77.52±5.95; p=0.016). There were no significant changes in TGF-β1 levels according to the 238 treatments in Ishikawa and USPC cells (Fig 5A and 5C) . The principal finding of our study was that tolerable doses of metformin alone ≤ 1000 248 µM have anti-invasive effects on KLE cells, and the anti-invasive effect of metformin is even 249 reversed by the addition of 10 µM MPA. Changes in the expression of MMP-9 and TGF-β1 250 were plausible mechanisms underlying these findings. We also showed that tolerable doses of 251 metformin alone, ≤ 1000, µM inhibited cell proliferation of Ishikawa, KLE, and USPC cells in 252 a dose-dependent manner. However, there was no additive or synergistic anti-proliferative 253 effect of metformin ≤ 1000 µM and MPA co-treatment in KLE and USPC cells.
254
MPA is recommended as a fertility-preserving treatment for young endometrial cancer 255 patients, as well as palliative treatment for terminally ill patients with hormone receptor-256 positive cancer, especially with PR; most of the MPA anticancer effects are known to act 257 through the interaction with PR (15). However, response rates of MPA are unsatisfying because 258 of the appearance of progesterone resistance; efforts were made to find an effective way to 259 overcome this (12, 15, 16) . Metformin was suggested to combine with MPA, based on several 260 mechanisms of reversing progesterone resistance, mainly as a potent inhibitor of the PI3K-261 AKT-mTOR pathway by activating AMPK. However, there were two issues to be solved. One 262 is the supra-therapeutic concentration of metformin. The activation of AMPK was almost 263 always demonstrated at an unrealistically high supra-therapeutic concentration of metformin, 13 264 considering the maximal dose in humans (without the risk of serious side effects) (16, 17) . The 265 other is that most of the findings were true only in Ishikawa cells, but not in other types of cells, 266 for example, KLE (12) . Therefore, we tried to find any anti-cancer effects of tolerable doses of 267 metformin with or without MPA in endometrial cancer cells with non-favorable clinical 268 behavior. 269 We found that metformin alone at ≤ 1000 µM significantly inhibited the proliferation 270 of all three cell lines ( Fig 1C-1E and 2) . The anti-proliferative effect of metformin alone at ≤ 
281
Other studies confirmed that there was no significant increase in p-AMPKα expression at low 282 doses of metformin, ≤ 1000 µM, in Ishikawa, KLE, and USPC cells (18, 19) . In these studies, 283 high dose metformin ≥10 mM was shown to be necessary to bring about a significant increase 284 in p-AMPKα expression. As there were no significant changes in PR and p-AMPKα levels in 285 KLE and USPC cells when metformin was combined with MPA (Fig 2) , we moved our focus 286 towards invasion; the plausible invasion mechanism was not related to the activation of AMPK.
287
It was interesting that the dose-dependent inhibitory effect of metformin ≤ 1000 µM 14 288 on cell invasion was found only in KLE cells, but not in Ishikawa and USPC cells. It was even 289 more interesting that the addition of MPA to metformin resulted in the opposite effects on cell 290 invasion in the two different types of cells, i.e. stimulating (reversing metformin effect) in KLE 291 and inhibitory (possible synergistic effect) in Ishikawa cells (Fig 3B and 3C) . The finding of 292 low dose metformin alone not conferring any change in invasion capability of Ishikawa cells 293 was consistent with that in a study of de Barros Machado et al. (20) . Even though we could not 294 find a plausible molecular mechanism for the synergistic anti-invasive effect of the narrow 295 dose window of metformin (0-100 µM) and MPA combination in Ishikawa cells (Fig 3B) , it is 296 notable that MMP-9 and TGF-β1 showed the same pattern of change to that of cell invasion 297 only in KLE cells (Fig 4 and 5) . MMP is known as one of the most essential proteases in the 298 proteolysis of extracellular matrix proteins and plays important roles in invasion and migration 299 (21). Unlike other relevant studies of MMPs in which the results were the same in MMP-2 and 300 MMP-9 (21-23), the results of our study were specific to MMP-9, but not MMP-2. TGF-β has 301 also been extensively studied as a crucial cytokine which promotes endometrial cancer invasion 302 and metastasis via epithelial mesenchymal transition (21, 23, 24) . MMPs and TGF-β form an 303 interplay loop in which one might activate the other and vice versa, to facilitate tumor 304 progression. The results of our study suggest that this loop could be inhibited by metformin at 305 doses as low as less than 1000 µM, but completely disinhibited or even stimulated by co- behavior. KLE cells could be clinically characterized as type II cancer cells because of the 309 aggressive behavior and poor outcomes, but also as type I due to the frequent PTEN and KRAS 310 mutations and rare p53 mutation, which are typical in type I cancer.
311
Despite a small number of studies, so far, addressing the anti-invasive and/or anti-migratory effects of metformin in endometrial cancer cells, this study is, to the best of our 313 knowledge, the first study which showed that the significant anti-invasive effect of a tolerable 314 dose of metformin in KLE cells was completely reversed to the state of no treatment by the 315 addition of MPA; these findings might be mediated through MMP-9 and TGF-β1. However, 316 our study has some limitations in that metformin was not shown as an AMPK activator.
317
However, there are a few studies which did not support metformin as a potent AMPK activator, 318 not only in proliferation (18), but also in invasion (22). Some values were out of the expected 319 ranges, for example, MMP-9 concentration after treatment with 1000 µM metformin only, 320 which was expected to be lower than that of 100 µM metformin. Lastly, treatment with 321 inhibitors such as GM6001 (an MMP inhibitor) could have made our results more confirmative.
322
Most studies on metformin and MPA in endometrial cancer have concluded that 323 combining the two could be a potential therapeutic strategy for overcoming progesterone 324 resistance (12, 15). However, our study suggests the possibility of the combination being 325 harmful instead of beneficial in some conditions, especially in clinically highly aggressive but 326 genetically type I cancer. Further animal studies are required to clinically confirm our study 327 findings.
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